Scarica l'app Stockscreener
35.34
3.30%
1.13
Pre-mercato:
36.40
1.06
+3.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$34.21
Aprire:
$34.37
Volume 24 ore:
803.31K
Relative Volume:
0.64
Capitalizzazione di mercato:
$2.04B
Reddito:
$11.13M
Utile/perdita netta:
$-105.04M
Rapporto P/E:
-15.66
EPS:
-2.2565
Flusso di cassa netto:
$-81.54M
1 W Prestazione:
+1.79%
1M Prestazione:
+21.44%
6M Prestazione:
+454.79%
1 anno Prestazione:
+196.48%
Intervallo 1D:
$33.76
$35.47
Intervallo di 1 settimana:
$33.44
$36.82
Portata 52W:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
35.34 | 2.04B | 11.13M | -105.04M | -81.54M | -2.2565 |
VRTX
Vertex Pharmaceuticals Inc
|
436.59 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.36 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
805.38 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.43 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.31 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Roth Capital Maintains Capricor Therapeutics (CAPR) Buy Recommendation - MSN
Top 10 healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x - MSN
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
CAPR Should I Buy - Intellectia AI
Capricor Therapeutics (CAPR) Leads Healthcare Stocks with High F - GuruFocus
Capricor Therapeutics stock jumps as FDA resumes Deramiocel review - MSN
Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Increases By 34.6% - MarketBeat
The Technical Signals Behind (CAPR) That Institutions Follow - Stock Traders Daily
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Roth MKM Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Capricor's Former Executive Considered for FDA Biologics Chief - Intellectia AI
CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.7%Should You Buy? - MarketBeat
Q3 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
[ARS] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan
Capricor Therapeutics | DEF 14A: Definitive information statements - Moomoo
Capricor Therapeutics (NASDAQ: CAPR) details 2026 meeting, board elections, pay and Deramiocel deals - Stock Titan
Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance - MSN
Aug Update: Is Capricor Therapeutics Inc stock a value trapMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Capricor Therapeutics, Inc.Common Stock (NQ: CAPR - The Chronicle-Journal
JPMorgan Chase Reduces Stake in Capricor Therapeutics - National Today
JPMorgan Chase & Co. Decreases Stock Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
Aug PreEarnings: Whats the profit margin of Capricor Therapeutics IncQuarterly Profit Summary & Consistent Income Trade Ideas - baoquankhu1.vn
Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones - Stock Traders Daily
Capricor Therapeutics (CAPR) Is Up 7.2% After HOPE-3 Data And PDUFA Update Has The Bull Case Changed? - Sahm
Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone - Sahm
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock - marketbeat.com
Capricor Therapeutics (CAPR) director sells 7,529 exercised shares - Stock Titan
Option exercise and 10b5-1 sales reported by CAPR (NASDAQ: CAPR) - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6%Here's Why - MarketBeat
Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock - marketbeat.com
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock - marketbeat.com
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 25,000 Shares of Stock - MarketBeat
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Capricor Therapeutics(CAPR.US) Director Sells US$3.52 Million in Common Stock - Moomoo
Capricor Therapeutics EVP Krasney sells $752k in shares By Investing.com - Investing.com Canada
Capricor Therapeutics director sells $3.5m in shares - Investing.com UK
Capricor Therapeutics director sells $3.5m in shares By Investing.com - Investing.com Australia
Capricor (NASDAQ: CAPR) EVP sells 25K shares after option exercises - Stock Titan
Director at Capricor (NASDAQ: CAPR) sells 115,000 shares via 10b5-1 plan - Stock Titan
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - MSN
Capricor Therapeutics (NASDAQ: CAPR) proxy: Board nominees, pay and Nippon Shinyaku deals - Stock Titan
[144] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan
Capricor Therapeutics Stock Rises Above 50-Day Average - National Today
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Insider Sell: Is Capricor Therapeutics Inc stock a good dividend stock2026 Price Momentum & Safe Capital Preservation Plans - baoquankhu1.vn
Value Recap: Is Capricor Therapeutics Inc a defensive stock2026 Levels & Weekly High Potential Stock Alerts - baoquankhu1.vn
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):